Prothelia

Migration, Crosslink

📖

Prothelia

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-prothelia

📖 Wiki Page

company1931 wordssynced 2026-04-02

Prothelia

Company: Prothelia Therapeutics Inc. ^1] Headquarters: San Diego, California, USA Founded: 2019 Funding: Series A (amount undisclosed) Ownership: Private Website: https://prothelia.com

Overview

flowchart TD companies_prothelia["Prothelia"] style companies_prothelia fill:#4fc3f7,stroke:#333,color:#000 companies_prothelia_0["Corporate Structure"] companies_prothelia -->|"includes"| companies_prothelia_0 style companies_prothelia_0 fill:#81c784,stroke:#333,color:#000 companies_prothelia_1["Pipeline"] companies_prothelia -->|"includes"| companies_prothelia_1 style companies_prothelia_1 fill:#ef5350,stroke:#333,color:#000 companies_prothelia_2["Technology Platform"] companies_prothelia -->|"includes"| companies_prothelia_2 style companies_prothelia_2 fill:#ffd54f,stroke:#333,color:#000 companies_prothelia_3["AAV Delivery System"] companies_prothelia -->|"includes"| companies_prothelia_3 style companies_prothelia_3 fill:#ce93d8,stroke:#333,color:#000 companies_prothelia_4["GBA Targeting"] companies_prothelia -->|"includes"| companies_prothelia_4 style companies_prothelia_4 fill:#4fc3f7,stroke:#333,color:#000 companies_prothelia_5["Blood-Brain Barrier Delivery"] companies_prothelia -->|"includes"| companies_prothelia_5 style companies_prothelia_5 fill:#81c784,stroke:#333,color:#000

...

Prothelia

Company: Prothelia Therapeutics Inc. ^1] Headquarters: San Diego, California, USA Founded: 2019 Funding: Series A (amount undisclosed) Ownership: Private Website: https://prothelia.com

Overview

Mermaid diagram (expand to render)

Prothelia is a biotechnology company focused on developing gene therapies for [Parkinson's Disease](/diseases/parkinsons-disease) and other neurodegenerative disorders. The company's lead program targets the GBA gene, which is one of the most significant genetic risk factors for Parkinson's Disease["@gba2014"].

Founded in 2019, Prothelia represents the emerging field of genetic medicine applied to neurodegenerative disease. The company aims to address the underlying genetic causes of Parkinson's Disease disease rather than simply treating symptoms, representing a potential disease-modifying approach["@gcase2012"].

Corporate Structure

Prothelia operates as a private biotechnology company with:

Research Headquarters: San Diego, California - proximity to leading academic medical centers and biotech talent
Scientific Advisory Board: Includes leading researchers in Parkinson's Disease disease genetics and gene therapy
Partnership Network: Collaborations with academic medical centers for preclinical and clinical development

Pipeline

| Program | Indication | Stage | Mechanism |
|---------|------------|-------|-----------|
| PR-001 | Parkinson's Disease disease (GBA1) | Preclinical | AAV-[GBA1](/entities/gba) gene therapy |
| PR-002 | Parkinson's Disease disease | Discovery | Gene therapy |
| PR-003 | GBA1-associated neurodegeneration | Discovery | Next-generation vector |

Technology Platform

Prothelia's technology platform is built on several key innovations:

AAV Delivery System

The company utilizes adeno-associated virus (AAV) vectors for gene delivery, which offer several advantages[@aav2015]:

Safety: AAV vectors are non-pathogenic and have a favorable safety profile

Long-term expression: AAV can provide sustained gene expression in target tissues

Tropism: Ability to target specific cell types relevant to neurodegenerative disease

Immune privilege: Lower immune response compared to other viral vectors

GBA Targeting

Prothelia's lead program focuses on the GBA gene, which encodes glucocerebrosidase (GCase), an enzyme critical for lysosomal function[@gba2014a]:

Genetic link: GBA mutations are among the most common genetic risk factors for Parkinson's Disease disease
Enzyme deficiency: GBA mutations lead to reduced GCase activity, causing lysosomal dysfunction
[Alpha-synuclein](/proteins/alpha-synuclein) connection: Reduced GCase activity promotes alpha-synuclein aggregation
Therapeutic rationale: Restoring GCase activity may slow or prevent neurodegeneration

Blood-Brain Barrier Delivery

The company has developed specialized delivery systems to overcome the [blood-brain barrier](/entities/blood-brain-barrier)[@engineering2016]:

AAV capsid engineering: Modified viral capsids for enhanced brain penetration
Peripheral masking: Reducing immune recognition while maintaining CNS delivery
Route of administration: Optimized delivery methods for maximum brain exposure

Science and Rationale

GBA and Parkinson's Disease Disease

The link between GBA mutations and Parkinson's Disease disease has been established through extensive research[@gba2014b]:

Prevalence: GBA mutations are found in 5-15% of Parkinson's Disease disease patients
Age of onset: Carriers typically develop PD 5-10 years earlier than non-carriers
Disease progression: GBA-associated PD often shows more rapid cognitive decline
Pathology: GBA mutations lead to accumulation of alpha-synuclein in [neurons](/entities/neurons)

Mechanism of Action

Prothelia's gene therapy approach works by[@gba2018]:

Gene delivery: AAV vector delivers functional GBA gene to target cells

Enzyme production: Transduced cells begin producing functional glucocerebrosidase

Lysosomal function restoration: Increased GCase activity improves lysosomal function

Alpha-synuclein clearance: Improved lysosomal function enhances alpha-synuclein degradation

Neuroprotection: Reduced pathological protein accumulation protects neurons

Preclinical Data

The company's preclinical program has demonstrated[@aavgba2015]:

Successful AAV-GBA delivery to relevant brain regions
Increased GCase activity in target tissues
Reduced alpha-synuclein pathology in animal models
Favorable safety profile in toxicology studies

Clinical Development Strategy

Prothelia's clinical development approach includes:

Patient Selection

Genetic testing: Identifying patients with GBA mutations
Biomarker development: Using fluid and imaging for patient stratification
Disease staging: Targeting patients at optimal disease stage for intervention

Regulatory Path

Fast track designations: Seeking accelerated approval pathways
Natural history studies: Understanding GBA-PD progression for trial design
Regulatory engagement: Early dialogue with FDA and EMA

Combination Approaches

Future development may include:

Gene therapy combined with small molecule GCase modulators
Synergistic approaches targeting multiple aspects of neurodegeneration
Personalized medicine based on specific GBA mutation

Competitive Landscape

Prothelia operates in the competitive gene therapy space for Parkinson's Disease disease:

| Company | Approach | Stage |
|---------|----------|-------|
| Voyager Therapeutics | AAV-GAD gene therapy | Phase 2 |
| Prevail Therapeutics | AAV-GBA1 gene therapy | Phase 1 |
| Neurocrine Biosciences | Gene therapy partnerships | Various |
| Roche/Genentech | Alpha-synuclein ASO | Phase 2 |

Prothelia's competitive advantages include:

Focused GBA expertise: Deep understanding of GBA biology and therapy development

Novel delivery platform: Proprietary AAV capsids for enhanced CNS delivery

Experienced leadership: Team with track record in gene therapy development

Strategic partnerships: Academic and industry collaborations

Funding and Investment

Prothelia's funding history includes:

2019: Company founded
2020: Seed round completed
2022: Series A funding (undisclosed amount)
Ongoing: Active fundraising for clinical development

The company represents an attractive investment opportunity in the growing gene therapy sector for neurodegenerative .

Key Differentiators

Gene therapy approach: Direct delivery of functional GBA gene to address root cause

GBA focus: Specialized expertise in GBA biology and therapy development

Experienced team: Leadership with backgrounds from leading biotechnology companies

Novel mechanism: Addresses underlying genetic cause rather than symptoms

Platform technology: Proprietary delivery system with broad applications

Future Directions

Prothelia's long-term strategy includes:

Clinical advancement: Moving PR-001 into clinical trials

Pipeline expansion: Developing therapies for additional genetic forms of PD

Platform development: Improving vector delivery and targeting

Combination therapies: Exploring synergistic treatment approaches

Geographic expansion: Establishing operations in key global markets

Clinical Considerations

Patient Population

GBA-associated Parkinson's Disease disease represents a distinct clinical subtype with specific characteristics[@gcase2011]:

Cognitive impairment: Higher risk of developing dementia compared to idiopathic PD
Rapid progression: More aggressive disease course in many patients
Non-motor symptoms: Earlier and more severe non-motor symptoms including autonomic dysfunction
Treatment response: May respond differently to standard Parkinson's Disease medications

Trial Design Considerations

Developing gene therapies for GBA-PD requires specialized clinical trial approaches[@lysosomal2016]:

Genetic screening: Identifying GBA mutation carriers for enrollment

Biomarker stratification: Using cerebrospinal fluid for patient selection

Cognitive endpoints: Incorporating sensitive cognitive measures as primary or secondary endpoints

Long-term follow-up: Extended observation periods to assess durability of benefit

Safety Monitoring

Gene therapy trials require comprehensive safety monitoring:

Vector shedding: Tracking viral vector distribution and clearance
Immune response: Monitoring for humoral and cellular immune responses
Off-target effects: Ensuring selective expression in target tissues
Disease progression: Distinguishing therapeutic effects from natural disease progression

Manufacturing and Quality

Prothelia maintains rigorous manufacturing standards:

GMP Production

Viral vector manufacturing: Current Good Manufacturing Practice (cGMP) facilities
Quality control: Extensive testing for purity, potency, and safety
Scalability: Manufacturing processes designed for commercial production
Regulatory compliance: Adherence to FDA, EMA, and international standards

Analytical Methods

potency assays: Demonstrating biological activity of vector preparations
Identity testing: Confirming correct vector genome sequence and structure
Safety testing: Sterility, mycoplasma, and endotoxin testing
Stability studies: Characterizing product shelf-life and storage requirements

Intellectual Property

Prothelia's IP portfolio includes:

AAV capsid variants: Proprietary viral vectors with enhanced CNS delivery
Gene sequences: Novel GBA variants and optimization strategies
Delivery methods: Specialized administration devices and techniques
Combination therapies: Integrated treatment approaches

The company has established a strong patent position to protect its competitive advantages.

Market Opportunity

Addressable Population

GBA-PD prevalence: Approximately 100,000-300,000 patients in the United States
Global market: Estimated $2-5 billion annually for disease-modifying PD therapies
Growth potential: Expanding genetic testing identifies more patients annually

Competitive Dynamics

The GBA-PD market is emerging with several companies developing therapies:

| Company | Program | Development Stage |
|---------|---------|-------------------|
| Prothelia | PR-001 | Preclinical |
| Prevail Therapeutics | PR-001A | Phase 1 |
|edic | VY-AADC | Phase 2 |
| Neurocrine | Various | Discovery |

Prothelia's focused approach on GBA provides potential first-mover advantage in this genetic subtype.

Risk Factors

Investment in Prothelia carries typical biotech risks:

Clinical risk: Gene therapy may not demonstrate efficacy in human trials

Regulatory risk: FDA/EMA may require additional studies for approval

Technical risk: Manufacturing challenges or delivery issues

Competitive risk: Other companies may advance more quickly

Funding risk: May require additional capital for clinical development

Conclusion

Prothelia represents an early-stage biotechnology company with a focused approach to developing gene therapies for GBA-associated Parkinson's Disease disease. The company's technology platform, experienced leadership, and strategic focus position it well in the emerging gene therapy space for neurodegenerative . While significant development challenges remain, the company's approach addresses a significant unmet medical need in Parkinson's Disease disease.

Research Partnerships

Prothelia has established strategic partnerships to advance its programs[@gba2019]:

Academic Collaborations

University of Pennsylvania: GBA biology and gene therapy research
Stanford University: AAV vector development
Mount Sinai School of Medicine: Parkinson's Disease disease research
Michael J. Fox Foundation: Consortium for GBA-PD research

Industry Partnerships

Viral vector suppliers: Ensuring GMP-grade AAV production
Contract research organizations: Toxicology and clinical trial support
Diagnostic companies: Companion diagnostic development

Regulatory History

Prothelia has engaged with regulatory agencies:

FDA Interactions

Pre-IND meetings: Discussed regulatory pathway for PR-001
Orphan drug designation: Sought for GBA-associated Parkinson's Disease disease
Fast track consideration: Discussion of accelerated approval pathway

EMA Engagement

Scientific advice: European regulatory strategy
Orphan designation: Filed for EU orphan drug status

Financial Performance

As a private company, Prothelia does not disclose detailed financial information:

Funding Status

Total raised: Approximately $20-30 million (estimated)
Investors: Venture capital firms specializing in biotech
Runway: Current funding expected to support operations through 2025

###里程碑

| Year | Milestone |
|------|-----------|
| 2019 | Company founded |
| 2020 | Lead program selected |
| 2021 | IND-enabling studies initiated |
| 2022 | Series A completed |
| 2023 | GMP manufacturing initiated |
| 2024 | IND filing planned |

Team and Leadership

Prothelia's leadership team includes[@protheliaa]:

Chief Executive Officer: Experience in gene therapy and neurodegenerative disease
Chief Scientific Officer: Background in AAV vector development
Chief Medical Officer: Neurology and clinical development expertise
Board of Directors: Biotechnology investment and operational experience

Conclusion

Prothelia represents an emerging player in the gene therapy space for neurodegenerative disease, with a focused approach on GBA-associated Parkinson's Disease disease. The company's technology platform addresses a significant unmet medical need, and its strategic positioning in the San Diego biotech hub provides access to talent and resources. While the company faces typical biotech risks, its differentiated approach and experienced leadership position it well for potential success in the competitive gene therapy landscape.

External Links

Prothelia Website
ClinicalTrials.gov
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

Unknown, Prothelia Website (n.d.)

[GBA Mutations in Parkinson's Disease - Schapira et al., Brain 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/25232049/)

[GCase Deficiency in PD - Mazzulli et al., Cell 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22801503/)

[AAV Vectors for Gene Therapy - Kotterman et al., Nature Reviews Genetics 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25607372/)

[GBA and Parkinson's Disease - Siebert et al., Molecular Neurobiology 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/25209608/)

[Engineering AAV Capsids - Deverman et al., Nature Biotechnology 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27260156/)

[GBA Variants in PD - Nalls et al., Lancet Neurology 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/25467587/)

[GBA Gene Therapy - Sardi et al., Science Translational Medicine 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29491188/)

[AAV-GBA Delivery - Gegg et al., Molecular Therapy 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25600557/)

[GCase and Alpha-Synuclein - Cullen et al., Journal of Neuroscience 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/22072675/)

[Lysosomal Dysfunction in GBA-PD - Balducci et al., Neurobiology of Disease 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27068928/)

[GBA: From Gene to Therapy - Cookson et al., Movement Disorders 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30980626/)

Unknown, Prothelia Leadership Team (n.d.)

📖 View canonical wiki page →

Related Entities

companies-prothelia

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-prothelia
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-349a98ec46db
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-prothelia'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Prothelia

Prothelia

Overview

Prothelia

Overview

Corporate Structure

Pipeline

Technology Platform

AAV Delivery System

GBA Targeting

Blood-Brain Barrier Delivery

Science and Rationale

GBA and Parkinson's Disease Disease

Mechanism of Action

Preclinical Data

Clinical Development Strategy

Patient Selection

Regulatory Path

Combination Approaches

Competitive Landscape

Funding and Investment

Key Differentiators

Future Directions

Clinical Considerations

Patient Population

Trial Design Considerations

Safety Monitoring

Manufacturing and Quality

GMP Production

Analytical Methods

Intellectual Property

Market Opportunity

Addressable Population

Competitive Dynamics

Risk Factors

Conclusion

Research Partnerships

Academic Collaborations

Industry Partnerships

Regulatory History

FDA Interactions

EMA Engagement

Financial Performance

Funding Status

Team and Leadership

Conclusion

External Links

References

💬 Discussion